Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCMSCs for fracture and bone nonunion
NCT02815423Phase 2Unknown
- Sponsor
- South China Institute for Stem Cell Biology and Regenerative Medicine
- Start
- Jan 2017
- Primary completion
- Jan 2019
- Modality
- Stem Cell Therapies
01
Overview
Phase 2, randomised, double-blind trial of human umbilical cord mesenchymal stem cells in bone fracture (Fx) and nonunion, sponsored by South China Institute for Stem Cell Biology and Regenerative Medicine. Primary endpoint: Radiological progression of bone fusion at 12 months. Status: unknown.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
bone fracture (Fx)nonunion
Beyond the preview
Go deeper on NCT02815423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02815423.